These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36836325)

  • 21. Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.
    Shirae S; Tsuruya Y; Kozaki T; Mizuhata J; Ose A
    J Clin Pharmacol; 2023 Jun; 63(6):704-714. PubMed ID: 36781411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
    Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
    J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study.
    Grensemann J; Pfaffendorf C; Wicha SG; König C; Roedl K; Jarczak D; Iwersen-Bergmann S; Manthey C; Kluge S; Fuhrmann V
    Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics of Ganciclovir in Critically Ill Patients.
    Krens SD; Hodiamont CJ; Juffermans NP; Mathôt RAA; van Hest RM
    Ther Drug Monit; 2020 Apr; 42(2):295-301. PubMed ID: 31425489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.
    Kriegl L; Hatzl S; Zurl C; Reisinger AC; Schilcher G; Eller P; Gringschl Y; Muhr T; Meinitzer A; Prattes J; Hoenigl M; Krause R
    J Antimicrob Chemother; 2022 Aug; 77(9):2500-2505. PubMed ID: 35726095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics.
    Cloesmeijer ME; van den Oever HLA; Mathôt RAA; Zeeman M; Kruisdijk-Gerritsen A; Bles CMA; Nassikovker P; de Meijer AR; van Steveninck FL; Arbouw MEL
    Br J Clin Pharmacol; 2020 Aug; 86(8):1620-1631. PubMed ID: 32150285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment.
    Huang H; Xie H; Chaphekar N; Xu R; Venkataramanan R; Wu X
    Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33619060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.
    Feys S; Gonçalves SM; Khan M; Choi S; Boeckx B; Chatelain D; Cunha C; Debaveye Y; Hermans G; Hertoghs M; Humblet-Baron S; Jacobs C; Lagrou K; Marcelis L; Maizel J; Meersseman P; Nyga R; Seldeslachts L; Starick MR; Thevissen K; Vandenbriele C; Vanderbeke L; Vande Velde G; Van Regenmortel N; Vanstapel A; Vanmassenhove S; Wilmer A; Van De Veerdonk FL; De Hertogh G; Mombaerts P; Lambrechts D; Carvalho A; Van Weyenbergh J; Wauters J
    Lancet Respir Med; 2022 Dec; 10(12):1147-1159. PubMed ID: 36029799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
    de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M
    Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients.
    Dinh TD; Nguyen HN; Le BH; Nguyen TTT; Nguyen HTL
    Infect Drug Resist; 2022; 15():4575-4583. PubMed ID: 36003989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia.
    Frymoyer A; Meng L; Bonifacio SL; Verotta D; Guglielmo BJ
    Pharmacotherapy; 2013 Jul; 33(7):718-26. PubMed ID: 23553582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
    Westermann I; Gastine S; Müller C; Rudolph W; Peters F; Bloos F; Pletz M; Hagel S
    Br J Clin Pharmacol; 2021 Nov; 87(11):4293-4303. PubMed ID: 33818823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization.
    Chantharit P; Tantasawat M; Kasai H; Tanigawara Y
    Ther Drug Monit; 2020 Dec; 42(6):872-879. PubMed ID: 32947557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
    Sridharan K; Abbasi MY; Mulubwa M
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.